Tetraphase Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, today provided a regulatory and clinical development update for eravacycline, the Company’s lead antibiotic candidate with potent activity against MDR pathogens, which is being developed for the treatment of serious and life-threatening bacterial infections. During the second half of 2017, Tetraphase plans to submit a Marketing Authorization Application to the European Medicines Agency for IV eravacycline for the treatment of cIAI.